A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

Primary Objective: • To determine the efficacy of sacituzumab govitecan and pembrolizumab combination treatment on pathological complete response (pCR)/residual cancer burden (RCB)-1 in the patients with early-stage TNBC who showed a resistance to the combination of immunochemotherapy. Secondary Objectives: * To determine the safety of the proposed combination treatment. * To determine the objective overall response rate (ORR) of the proposed treatment. * To determine the distant-recurrence-free survival (DRFS). * To determine the 3-year event-free survival (EFS) rate. * To determine the 3-year overall survival (OS) rate. Exploratory Objective: • To investigate the response biomarkers in the tumor tissues and peripheral blood.